The intervention group consisted of patients who were prescribed GLP-1 RA medications, including Victoza (Liraglutide 1.8 mg), Saxenda (Liraglutide 3 mg), Ozempic (Semaglutide 1 mg), and Wegovy (Semaglutide 2.4 mg)
Most patients reach the 2.4 mg maintenance dose around week 17, after four titration steps
I couldnt swear that the reduced hunger Im feeling is a result of the semaglutide, rather than simply being due to the placebo effect of being told (and believing!) that my appetite is going to decrease, and that my feelings of fullness are going to increase (semaglutide does two main things, in weight loss terms: it slows digestion, meaning you feel fuller for longer, and it reduces appetite)
Reported Effects Weight reduction (no diabetes): In REDEFINE 1, CagriSema 2.4 mg + 2.4 mg produced roughly 22.7% mean weight loss at 68 weeks (trial-product estimand), though this fell short of the ~25% Novo Nordisk had guided toward [1]